Introduction {#s1}
============

Exposure to environmental chemicals in the air, water, soil, food, and consumer products, whether intentional or not, is an everyday occurrence ([@c1]). Because global chemical production and usage are projected to increase in the coming decades ([@c234]), there is a growing recognition that, although many comforts of modern life are due in part to chemicals that are on the market today, their sound management is critical for the preservation of human health and the environment ([@c211]).

A recent assessment by an expert panel convened by the World Health Organization estimated that as many as 20% of cancers, 31% of cardiovascular diseases, 42% of stroke cases, and 35% of chronic obstructive pulmonary disease cases are attributable to environmental factors ([@c247]). Chronic illnesses that may be caused or exacerbated by environmental chemicals include asthma, obesity, Alzheimer's disease, diabetes, infertility, and ovarian dysgenesis syndrome (reviewed by [@c28]). Taken together, it has been estimated that the health and socioeconomic costs associated with environmental chemical exposure are likely to exceed 10% of the global gross domestic product, amounting to approximately \$6.23 trillion ([@c116]).

These reports indicate that there are major inadequacies in current risk assessment and hazard management practices. First, toxicity studies are generally conducted with individual chemicals with the objective of providing an estimated point of departure ([@c113]). Such assessments, although undoubtedly useful, are ineffective at predicting the hazardous effects of chemicals that exhibit nonmonotonic dose responses and low dose relationships (reviewed by [@c303]) and fail to account for mixture effects (reviewed by [@c28]). An additional challenge is that a subgroup of these chemicals, endocrine-disrupting chemicals (EDCs), can mimic or alter endogenous endocrine processes ([@c4]). Therefore, it is often challenging to disentangle the effects of environmental hazards (such as EDCs) from those of inherent differences within and between populations ([@c228]). Indeed, multiple reports have shown that the effects of an exposure could differ in individuals depending on the individuals' age or sex ([@c1]). The burden of environmental hazards is reported to be inequitably distributed according to socioeconomic status, disproportionately affecting vulnerable populations ([@c46]). Moreover, efforts to pinpoint associations between environmental chemicals and health effects in longitudinal studies are often complicated by the fact that chemical environments change relatively rapidly over time ([@c170]).

To date, several major classes of hazardous or potentially hazardous environmental chemicals have been identified. These include toxic elements (e.g., arsenic, cadmium, lead, mercury); naturally occurring animal, plant, and food allergens; pesticides, persistent organic pollutants (e.g., perfluorooctanoic acid, polychlorinated biphenyls); volatile organic compounds (e.g., benzene, formaldehyde, gasoline); plastic components (e.g., bisphenol A, phthalates); and air pollutants (e.g., asbestos, radon, tobacco smoke) (reviewed by [@c28]; [@c264]). Biochemical effects commonly reported to be triggered by environmental toxicants include oxidative stress, endocrine disruption, genotoxicity, enzyme inhibition, epigenetic changes, and dysbiosis (reviewed by [@c129]; [@c264]). Evidently, there is a need for a concerted effort across all levels to understand and mitigate the impact of toxic exposures on human health and the environment.

A compelling puzzle in the field is the observation that a subgroup of environmental toxicants can induce persistent phenotypic effects after transient exposures, generating adverse effects that can be manifested years or even generations later ([@c114]; [@c270]; [@c299]; [@c302]). Although the mechanisms by which these long-lasting or transgenerational adverse effects occur have yet to be fully elucidated, one explanation for this phenomenon is that environmental toxicants could perturb epigenetic mechanisms ([@c309]). Described as the interface between the environment and the genome, epigenetic marks are responsive to environmental stimuli and transmissible and are, therefore, promising mechanisms by which the effects of environmental toxicants are perpetuated ([@c131]).

In this commentary, we discuss the impact that environmental chemicals can have on epigenetic regulation, the impacts of chemical-induced epigenetic changes on health outcomes, current risk assessment strategies for detecting epigenetic modifiers, and the unique challenges of and strategies for incorporating epigenomic analyses in toxicology.

Epigenetics and Its Growing Role in Environmental Epidemiology {#s1.1}
--------------------------------------------------------------

Epigenetic mechanisms refer collectively to mitotically or meiotically heritable alterations in gene expression (and associated phenotypic traits) that do not arise from changes in DNA nucleotide sequences (reviewed by [@c31]; [@c100]). The definition of epigenetics encompasses chromatin modifications that directly influence chromatin conformation (i.e., DNA methylation and histone posttranslational modifications), as well as the activity of noncoding RNAs (ncRNAs), in view of accumulating evidence that ncRNAs can influence chromatin conformation and induce heritable effects ([@c13]; [@c40]; [@c48]; [@c51]; [@c94]; [@c96]; [@c107]; [@c179]) ([Figure 1](#f1){ref-type="fig"}). Although these three modes of epigenetic regulation converge on a common cellular process (i.e., regulating gene expression), the mechanisms may act with different degrees of dynamic effects, strengths, and reversibility ([@c30]). Moreover, although they are often studied independently, it is becoming increasingly clear that there is extensive cross-talk between DNA methylation, histone modifications, and ncRNAs ([@c124]; [@c256]; [@c300]).

![Diagrammatical summary of epigenetic modes on action. (A) The deposition of methyl groups is mediated by the DNA methyltransferases (DNMTs), and their removal is mediated by the ten-eleven translocation (TET) family proteins (reviewed by [@c117]; [@c327]). Increased deposition of methyl groups promotes the condensation of chromatin, whereas reduced DNA methylation is associated with increased accessibility to transcription machinery \[represented by RNA polymerase II (Pol II)\]. DNA hypermethylation generally leads to the silencing of gene expression when it occurs at gene promoters (reviewed by [@c117]; [@c327]). (B) Histone modifications are deposited by multiple classes of enzymes \[histone acetyltransferases (HATs), histone methyltransferases (HMTs), histone deacetylases (HDACs), and histone lysine demethylases (KDMs)\] (reviewed by [@c63]). Examples of histone modifications illustrated here are histone H3 lysine 27 trimethylation (H3K27me3) and H3 lysine 9 trimethylation (H3K9me3), which are usually associated with repression of gene transcription, and H3 lysine 4 monomethylation (H3K4me1), H3 lysine 4 trimethylation (H3K4me3), H3 lysine 36 trimethylation (H3K36me3), and H3 lysine 27 acetylation (H3K27ac) marks that are typically associated with activation of transcription. Simultaneous deposition of opposing histone marks is associated with poised or bivalent chromatin, which is in a transitional state poised to be resolved into active or repressed states (reviewed by [@c63]). (C) microRNAs (miRNAs) bound to the Argonaute (AGO) protein make up the miRNA-induced silencing complex (miRISC). miRNAs direct the miRISC to target mRNAs base-pairing partially to complementary binding sites, which will be cleaved by catalytically active AGO proteins ([@c233]). Alternatively, AGO proteins can recruit additional protein partners, initiating the process of deadenylation, decapping and 5ʹ-to-3ʹ mRNA degradation by 5ʹ-to-3ʹ exoribonuclease 1 (XRN1) (reviewed by [@c150]). There has also been evidence that miRNAs inhibit translation by inhibiting the eukaryotic initiation factor 4F (eIF4F) complex, although this process has yet to be fully elucidated (reviewed by [@c150]). 5ʹ polyA tails are denoted by circles labeled A. (D) Long noncoding RNAs (lncRNAs) may influence gene expression by increasing or decreasing target mRNA stability, by acting as decoys to miRNA and transcription factors (TFs), thus sequestering them from their cognate promoters, or they may recruit or inhibit TF binding to their target sites on the chromatin (reviewed by [@c9]). lncRNAs may also recruit chromatin remodeling factors (CRFs) such as the polycomb repressive complexes or cohesin proteins that recruit histone modifier complexes or initiate long-range chromatin looping (reviewed by [@c9]). The Xist lncRNA triggers stable repression of the presumptive inactive X-chromosome by physically coating the X-chromosome (reviewed by [@c176]).](ehp-128-015001-g001){#f1}

Epigenetic mechanisms regulate transcriptional activity across the genome and can thereby determine temporal and spatial gene expression patterns ([@c22]; [@c144]). The heritability of epigenetic marks allows for faithful maintenance of cell identity ([@c175]), whereas their reversibility allows for developmental plasticity, enabling the manifestation of different phenotypes in response to developmental cues and environmentally induced changes from a single unchanged genotype ([@c194]). Although some degree of stochastic epigenetic alterations, or epigenetic drift, can be observed in aging or as asymptomatic occurrences ([@c32]; [@c100]; [@c103]; [@c323]), epigenetic aberrations have been described as important drivers of neurological diseases and cancer ([@c129]; [@c346]). Therefore, external stimuli that can cause shifts away from baseline rates of age-related epigenetic drift have been described as elements that cause "environmental deflection" ([@c160]).

Moreover, epigenetics can provide key mechanistic evidence for the developmental origins of health and disease (DOHaD) hypothesis ([@c115]). The DOHaD concept was proposed as a means to explain epidemiological evidence linking early life exposure to environmental factors with the onset of adverse health effects later in life ([@c18]; [@c19]; [@c27]). DOHaD proposes that early developmental stages are windows of vulnerability to psycho-social or chemical stressors. Hence, relatively small alterations at this stage of life could have impacts on risk of diseases across the life course into adulthood. This is in line with the notion that profound epigenetic reprograming, characterized by a sequential genome-wide erasure and *de novo* lineage-specific establishment of epigenetic marks, underlies pluripotency and lineage commitment, which occur early in embryonic development ([@c175]). Thus, perturbations during this window of development could enable the propagation of aberrant epigenetic patterns and associated gene activity states at doses of exposure that would otherwise be biologically inconsequential ([@c12]; [@c42]).

Environmental Toxicants as Disruptors of Epigenetic Regulation {#s1.2}
--------------------------------------------------------------

Following the frequent inclusion of epigenetics as a parameter in environmental epidemiology studies, numerous reports have been made in recent years associating alterations in DNA methylation with various environmental factors, including biological agents, dietary habits, and air pollution ([@c5]; [@c18]; [@c76]; [@c78]; [@c98]; [@c100]; [@c126]; [@c129]; [@c208]; [@c238]; [@c325]). Similarly, many reports indicate that microRNA (miRNA) profiles are responsive to various environmental exposures, including air pollution \[R Chen et al. ([@c62]); Espín-Pérez et al. ([@c93]), both epidemiological studies\], nanoparticles \[Brzóska et al. ([@c47]), utilizing human liver cells\], endocrine disruptors, such as bisphenol A (BPA) \[Chou et al. ([@c67]), using human endometrial cells, and Martínez-Ibarra et al. ([@c210]), using human blood samples\], and dichlorodiphenyltrichloroethane (DDT) \[Krauskopf et al. ([@c162]), using human blood\]. Long noncoding RNAs (lncRNAs), although still a relatively new area of research, have been reported to be associated with levels of phthalates in first trimester urine of pregnant women ([@c172]), benzene in seven exposed individuals ([@c16]), and occupational exposure to cadmium ([@c343]) and to be responsive to developmental exposure to BPA in mice ([@c164]) and to certain heavy metals in *in vitro* ([@c288]; [@c343]) and *in vivo* experimental systems ([@c343]). Alterations to histone marks have been reported in response to various substances including arsenic in mice ([@c72]) and in cell lines ([@c149]; [@c182]; [@c342]), BPA \[Senyildiz et al. ([@c266]), using human neuroblastoma cells\], phthalates \[Sonkar et al. ([@c276]), in mesenchymal stem cells\], and dichlorodiphenyltrichloroethane \[Ben Maamar et al. ([@c24]), in male rats descended from exposed gestating female rats\].

[Table 1](#t1){ref-type="table"} provides a non-exhaustive summary of environmental chemicals with demonstrated epigenome-altering properties. Here, we discuss three salient examples, namely, benzene, vinclozolin, and BPA, in greater detail.

###### 

Summary of evidence of environmental chemicals and their effect on epigenetic regulation.

Table 1 has eight columns, namely, environmental chemicals, human, animal, and in-vitro experimental evidence, observational evidence for human and animal, epigenetic impact, and references.

  Environmental chemicals                                                                          Experimental evidence                                                                                                                  Observational evidence   Epigenetic impact   References                                
  ------------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------------------------------------------------------- ------------------------ ------------------- ------------ ----- ---------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Organic pollutants                                                                                                                                                                                                                                                                                                             
   2,3,7,8-tetrachloro-dibenzo-*p*-dioxin                                                          ---                                                                                                                                    \+                       \+                  ---          ---   DNA methylation        [@c21]; [@c81]
   Benzene                                                                                         ---                                                                                                                                    \+                       \+                  \+           ---   DNA methylation        [@c36]; [@c70]; [@c105]; [@c135]; [@c146]; [@c184]; [@c267]; [@c331]
  Histone marks                                                                                    [@c183]                                                                                                                                                                                                                       
  Noncoding RNA                                                                                    [@c15]; [@c191]; [@c318]                                                                                                                                                                                                      
   BPA                                                                                             ---                                                                                                                                    \+                       \+                  \+           ---   DNA methylation        [@c8], [@c7]; [@c17]; [@c20]; [@c21]; [@c45]; [@c66]; [@c87]; [@c89], [@c88]; [@c90]; [@c110]; [@c112]; [@c133]; [@c142]; [@c143]; [@c151]; [@c157]; [@c165]; [@c167]; [@c169]; [@c178]; [@c181]; [@c185]; [@c190]; [@c205]; [@c225]; [@c232]; [@c237]; [@c245]; [@c266]; [@c285]; [@c286]; [@c289]; [@c316]; [@c319]; [@c334]
  Histone marks                                                                                    [@c85]; [@c110]; [@c132]; [@c138]; [@c148]; [@c165]; [@c178]; [@c185]; [@c192]; [@c239]; [@c258]; [@c266]; [@c308]; [@c315]; [@c316]                                                                                          
  Noncoding RNAs                                                                                   [@c26]; [@c67]; [@c132]; [@c164]; [@c239]; [@c251]                                                                                                                                                                            
   BPA substitutes (bisphenol AF, F, and S)                                                        ---                                                                                                                                    \+                       \+                  ---          ---   DNA methylation        [@c136]
  Histone marks                                                                                    [@c83]                                                                                                                                                                                                                        
  Noncoding RNAs                                                                                   [@c308]                                                                                                                                                                                                                       
   Endosulfan                                                                                      ---                                                                                                                                    \+                       ---                 ---          ---   DNA methylation        [@c226]
   Glyphosate                                                                                      ---                                                                                                                                    \+                       ---                 ---          ---   DNA methylation        [@c272]
   Hexachlorobenzene                                                                               ---                                                                                                                                    ---                      \+                  ---          ---   DNA methylation        [@c21]
   Methoxychlor                                                                                    ---                                                                                                                                    \+                       ---                 ---          ---   DNA methylation        [@c12]; [@c281]; [@c114]; [@c203]; [@c337]
   *n*-Butylparaben                                                                                ---                                                                                                                                    \+                       ---                 ---          ---   DNA methylation        [@c338]
   Organophosphate flame-retardant (e.g., BDE-47, tetrabromobisphenol A)                           ---                                                                                                                                    \+                       \+                  \+           ---   DNA methylation        [@c21]; [@c52]; [@c277]
  Histone marks                                                                                    [@c235]                                                                                                                                                                                                                       
   Phenols (e.g., 4-nonylphenol, 4-octylphenol)                                                    ---                                                                                                                                    ---                      \+                  ---          ---   Histone marks          [@c109]; [@c137]
   Phthalates                                                                                      ---                                                                                                                                    \+                       \+                  \+           ---   DNA methylation        [@c59]; [@c60]; [@c118]; [@c172]; [@c209]; [@c273]; [@c279]; [@c291]; [@c326]; [@c328]; [@c333]
  Histone marks                                                                                    [@c122]; [@c276]                                                                                                                                                                                                              
  Noncoding RNAs                                                                                   [@c173]; [@c198]; [@c210]; [@c222]; [@c279]; [@c341]                                                                                                                                                                          
   Polyhalogenated biphenyls (e.g., polybrominated biphenyl and polychlorinated biphenyls)         ---                                                                                                                                    \+                       \+                  \+           ---   DNA methylation        [@c21]; [@c74]; [@c212]; [@c246]
  Histone marks                                                                                    [@c55]                                                                                                                                                                                                                        
   *p,pʹ*-DDE                                                                                      ---                                                                                                                                    \+                       ---                 ---          ---   DNA methylation        [@c274]; [@c275]
  Pharmaceutical compounds                                                                                                                                                                                                                                                                                                       
   Cyproterone acetate                                                                             ---                                                                                                                                    ---                      \+                  ---          ---   Nucleosome occupancy   [@c11]
   Diethylstilbestrol                                                                              ---                                                                                                                                    \+                       \+                  ---          ---   DNA methylation        [@c21]; [@c44]; [@c60]; [@c269]
  Histone marks                                                                                    [@c145]; [@c260], [@c261]; [@c269]                                                                                                                                                                                            
  Noncoding RNA                                                                                    [@c26]; [@c236]; [@c269]; [@c279]                                                                                                                                                                                             
   Exogenous estrogen (e.g., ethinyl estradiol, estradiol benzoate)                                ---                                                                                                                                    \+                       \+                  ---          ---   DNA methylation        [@c64]; [@c66]; [@c75]; [@c114]; [@c133]; [@c224]; [@c301]; [@c332]
  Noncoding RNA                                                                                    [@c199]; [@c224]                                                                                                                                                                                                              
   Tamoxifen                                                                                       ---                                                                                                                                    \+                       \+                  ---          ---   DNA methylation        [@c280]; [@c293]
  Nucleosome occupancy                                                                             [@c11]                                                                                                                                                                                                                        
  Histone marks                                                                                    [@c294]                                                                                                                                                                                                                       
  Dietary compounds                                                                                                                                                                                                                                                                                                              
   Epigallocatechin gallate                                                                        ---                                                                                                                                    \+                       ---                 ---          ---   Histone marks          [@c192]
   Phytoestrogens (e.g., genistein, resveratrol, and daidzein)                                     \+                                                                                                                                     \+                       \+                  ---          ---   DNA methylation        [@c2]; [@c39]; [@c87]; [@c104]; [@c143]; [@c152]; [@c193]; [@c200]; [@c248]; [@c287]; [@c305]; [@c329]
  Histone marks                                                                                    [@c152]; [@c201], [@c200]; [@c307]                                                                                                                                                                                            
  Mixtures                                                                                                                                                                                                                                                                                                                       
   Mixed contaminants (industrial chemicals, e.g., *p,pʹ*-DDE, Li, Fe, Ni, Sb, Pb, Bi, V, As, S)   ---                                                                                                                                    ---                      ---                 ---          \+    DNA methylation        [@c121]
   Mixture---plastic derived EDCs (BPA, DEHP, DBP)                                                 ---                                                                                                                                    \+                       ---                 ---          ---   DNA methylation        [@c204]
   Total xenoestrogens                                                                             ---                                                                                                                                    ---                      ---                 \+           ---   DNA methylation        [@c310]
  Others                                                                                                                                                                                                                                                                                                                         
   Metals (e.g., inorganic As, Cd, Cr, Pb)                                                         ---                                                                                                                                    \+                       \+                  \+           ---   DNA methylation        [@c56]; [@c86]; [@c218]; [@c244]; [@c255]; [@c265]; [@c271]; [@c321]
  Histone marks                                                                                    [@c72]; [@c149]; [@c182]; [@c321]; [@c342]; [@c344]                                                                                                                                                                           
  Chromatin accessibility                                                                          [@c313]                                                                                                                                                                                                                       
  Noncoding RNA                                                                                    [@c65]                                                                                                                                                                                                                        
   Tetrahydrofurandiols                                                                            ---                                                                                                                                    \+                       ---                 ---          ---   Histone marks          [@c268]
   Vinclozolin                                                                                     ---                                                                                                                                    \+                       ---                 \+           ---   DNA methylation        [@c12]; [@c23]; [@c111]; [@c120], [@c119]; [@c141]; [@c177]; [@c213]; [@c243]
  Histone retention sites                                                                          [@c24]                                                                                                                                                                                                                        
  Noncoding RNAs                                                                                   [@c43]; [@c263]                                                                                                                                                                                                               
   Zearalenone                                                                                     ---                                                                                                                                    \+                       \+                  ---          ---   DNA methylation        [@c106]; [@c153]; [@c220]
  Histone marks                                                                                    [@c106]; [@c220]                                                                                                                                                                                                              

Note: Animal studies include findings in both vertebrate and invertebrate models. Plus signs (+) indicate that there is evidence that the compound(s) in question exhibits epigenetic-modulating properties in the systems specified. ---, Not applicable; As, arsenic; BDE 47, tetrabromodiphenyl ether; Bi, bismuth; BPA, bisphenol A; Cd, cadmium; Cr, chromium; DBP, dibutyl phthalate; DEHP, di-2-ethylhexyl phthalate; EDC, endocrine-disrupting chemical; Fe, iron; Li, lithium; Ni, nickel; Pb, lead; *p,p*ʹ-DDE, *p,p*ʹ-dichlorodiphenoxydichloroethylene; S, sulfur; Sb, antimony; V, vanadium.

Benzene---Epigenome Perturbations at Low-Level Exposures {#s1.3}
--------------------------------------------------------

Benzene, a common aromatic compound in crude oils, is a human carcinogen ([@c139]) and may be one of the most potent epigenetic modifiers in the environment. Airborne, occupational exposure to benzene has been consistently associated with hypomethylation in repetitive elements in peripheral blood DNA obtained from occupationally exposed individuals ([@c36]; [@c105]; [@c267]) and is associated with lower levels of $O^{6}$-methylguanine-DNA methyltransferase (MGMT) promoter methylation in whole blood DNA ([@c184]). Of note, significant differential methylation was reported between a group of individuals with a median personal benzene exposure of $22{\,\mu g/m}^{3}$ ([@c36]) and in individuals exposed to a median 8-h time-weighted average benzene exposure of $110{\,\mu g/m}^{3}$ ([@c184]), both of which are below the National Institute of Occupational Safety and Health's recommended exposure limit for benzene ($320{\,\mu g/m}^{3}$) ([@c231]). Similarly, individuals exposed to benzene at median concentrations of $120{\,\mu g/m}^{3}$ had significantly higher global levels of H3 lysine 4 trimethylation (H3K4me3) marks compared with a control group ([@c183]). Perturbations to miRNA ([@c15]; [@c191]) and lncRNA ([@c16]) expression have likewise been detected in pooled plasma ([@c191]) and peripheral blood mononuclear cell ([@c15], [@c16]) samples of benzene-exposed individuals. Although it has been reported that environmental exposures to benzene also affect the transcriptome in blood mononuclear cells ([@c216], [@c217]), the direct contribution of benzene-induced epigenetic alterations to the transcriptome remains to be established.

Benzene and some of its metabolites have also been shown to induce global hypomethylation in *in vitro* ([@c70]; [@c135]; [@c146]) and *in vivo* ([@c240]) experimental systems, recapitulating the effects observed in exposed humans. Cells subjected to multiple rounds of exposure to hydroquinone, a benzene metabolite, over a period of 5 weeks exhibited a gradual increase in the levels of H3K4me3, an active histone mark ([@c202]). In mice, exposure to benzene was associated with lower levels of peripheral blood cells and hematopoietic progenitor cells in the bone marrow and alterations to the miRNAs mmu-miR-34a-5p; mmu-miR-342-3p; mmu-miR-100-5p, mmu-miR-181a-5p, and mmu-miR-196b-5p, many of which are dysregulated in hematological malignancies ([@c318]).

Vinclozolin---Transgenerational Impacts on the Epigenome {#s1.4}
--------------------------------------------------------

Vinclozolin is a dicarboximide fungicide used on fruits, vegetables, ornamental plants, and turf grass and is a prominent example of an environmental toxicant capable of triggering adverse health effects long after the initial exposure ([@c299]). Mice exposed to vinclozolin *in utero* displayed significantly higher numbers of apoptotic germ cells at puberty \[postnatal day (PND) 20\], an effect that became more pronounced in adulthood (PND60) ([@c299]). Moreover, maternal exposure to vinclozolin negatively affected fertility in male mice in the descendent F1 generation and epigenetic alterations in more than 1,000 targets (primarily hypomethylation events) compared with controls ([@c177]). Guerrero-Bosagna et al. ([@c119]) further observed that differential DNA methylation patterns could be observed up to the F3 generation of vinclozolin-lineage mice ([@c119]). Interestingly, administration of vinclozolin to pregnant mice led to higher levels of DNA methylation in the promoters of two paternally imprinted genes \[imprinted maternally expressed transcript (*H19*) and maternally expressed 3 (*Gtl2*) also known as Meg3\] and lower levels of DNA methylation in regions regulating three maternally imprinted genes \[small nuclear ribonucleoprotein polypeptide N (*Snrpn*), paternally-expressed Gene 1 (*Peg1*) also known as Mest, and paternally expressed 3 (*Peg3*)\] ([@c282]). In Sprague-Dawley rats, alterations in more than 200 small ncRNAs ([@c263]) and 99 histone retention sites ([@c24]) were observed in the sperm from the F3 generation of vinclozolin-lineage rats compared with the control group. The F3 generation of vinclozolin-lineage male rats had higher incidence of prostate histopathology and abnormalities and displayed altered gene expression, ncRNA expression, and DNA methylation patterns compared with the untreated controls ([@c158]).

Because the abovementioned studies suggest that vinclozolin can induce transgenerational epigenetic effects, it stands to reason that differential epigenetic marks observed in the F3 generation should also be present in the F1 and F2 generations of the vinclozolin-lineage rats or mice. Intriguingly, however, analyses of F1 and F3 vinclozolin-lineage rats revealed that although there were a total of 290 differentially methylated regions (DMRs) ($p < 10^{- 4}$) in the F1 generation (control vs. vinclozolin-lineage animals) and a total of 916 total DMRs in the F3 generation, there was no overlap between the F1 and F3 DMRs ([@c23]). This indicates that the epigenetic alterations accumulated in vinclozolin-lineage rats or mice are not directly inherited by subsequent generations. Instead, exposure could result in alterations to developmental programing and epigenetic mechanisms in early generations that are transmitted to subsequent generations, amplifying differences in epigenetic patterns between control and exposure-lineage mice.

One caveat to these findings, however, is that the transgenerational epigenetic effects of vinclozolin were reported in studies using intraperitoneal administration of vinclozolin at $100\;{mg}/{kg}$ body weight per day ([@c24]; [@c177]; [@c230]; [@c282]; [@c299]). This is orders of magnitude above the calculated chronic population adjusted dose of $0.0012\;{mg}/{kg}\text{ \ per\  \ day}$ ([@c295]) or the estimated occupational exposure in production workers ($0.012\;{mg}/{kg}\text{ \ per\  \ day}$) ([@c345]). To our knowledge, there is currently no evidence that vinclozolin induces transgenerational effects when administered at lower doses and via dermal and/or oral routes, which are arguably closer to the likely routes of vinclozolin exposure in humans.

Bisphenol A---a Stealthy Hazard {#s1.5}
-------------------------------

No summary on environmental toxicants could be complete without the mention of BPA. BPA is now a household name, and it is not uncommon to see "BPA-free" statements on plastic products or printed material. Despite efforts to limit the usage of BPA, BPA production is predicted to increase in the coming decades (reviewed by [@c3]). BPA is a known endocrine disruptor, exhibiting agonistic effects on both estrogen receptors alpha and beta ($\text{ER}\alpha\text{ \ and\  \ ER}\beta$), and antagonistic effects on the androgen receptor ([@c80]). A wide range of health effects have been associated with BPA exposure, including obesity, reduced reproductive capacity, and metabolic disease ([@c204]). Traces of BPA were detected in 92.6% of sampled participants from the National Health and Nutrition Examination Survey (NHANES) ([@c53]), suggesting that exposure to BPA is nearly ubiquitous.

BPA exposure has been consistently associated with hypomethylation in repetitive elements in humans ([@c99]; [@c225]; [@c340]). In a cross-sectional human study, multivariate analysis indicated that workplace BPA exposure was associated with significantly lower long interspersed nuclear element 1 (LINE-1) methylation levels relative to an unexposed control group, and that urine BPA levels were significantly inversely associated with LINE-1 methylation in sperm ([@c225]). In corroboration with this, a similar study reported that sperm collected from BPA-exposed men exhibited 19.6% higher levels of global 5-hydroxymethylcytosine, an intermediate of the demethylating process by ten-eleven translocation (TET) enzymes, compared with men without occupational exposure to BPA ([@c340]). Interestingly, an epigenome-wide study on human fetal liver tissue reported that although exposure was generally associated with global hypomethylation, increasing BPA levels were positively correlated with hypermethylation of CpG islands, suggesting that the effects of BPA on DNA methylation and gene expression are genomic region-dependent ([@c99]). *In utero* exposure to BPA was also found to induce persistent epigenetic effects. Using data from a longitudinal birth cohort, Goodrich et al. ([@c112]) reported that blood leukocyte DNA methylation in participating peri-adolescents was positively correlated with increasing BPA levels both in archived maternal urinary samples collected during the third trimester of pregnancy and in the urinary samples obtained from the peri-adolescents themselves. Although this positive correlation was observed at all analyzed loci, namely, the LINE-1 repetitive elements, and imprinted genes *H19*, *IGF2*, and *HSD11B2*, statistical significance was observed only when associating maternal urinary BPA levels with *IGF2* hypermethylation ([@c112]). However, these findings are not completely concordant with the previously described results in human subjects whereby BPA exposure was associated with decreased LINE-1 methylation. Nevertheless, taken together, these reports suggest that environmentally relevant concentrations of BPA can affect the epigenome.

The effect of BPA on the epigenome, including persistent and early life effects, has been demonstrated in numerous experimental models ([Table 1](#t1){ref-type="table"}). For example, prenatal exposure to BPA resulted in dysregulated expression of the lncRNAs *Xist* and its antisense *Tsix* in the mouse brain, suggesting that *in utero* BPA exposure during the critical period of brain development may affect neurodevelopment through the deregulation of epigenetic mechanisms involved in X-chromosome inactivation ([@c164]). Epigenetic alterations were detected in mice exposed to environmentally relevant doses (as low as $50\text{ \ ng}/{kg}$) of BPA during development ([@c8]). Similarly, rats exposed to transient, environmentally relevant doses of BPA exhibited greater prostate gland susceptibility to adult-onset precancerous lesions and persistent alterations in DNA methylation patterns ([@c133]).

However, it is worth noting that studies on BPA have not been immune to flaws in design and execution. An expert opinion on the design and execution of the Consortium Linking Academic and Regulatory Insights on BPA Toxicity (CLARITY-BPA) study has highlighted that the use of gavage as a route of exposure, without a nongavaged negative control, could complicate the interpretation of the results and lead to erroneous conclusions ([@c312]). This argument was previously made by Vandenberg et al. ([@c304]) in the context of EDCs ([@c304]), indicating that further review and reconsideration of supposedly established methods may be in order.

Discussion {#s2}
==========

Epigenetic Marks in Risk Assessment {#s2.1}
-----------------------------------

As described in the previous section, stable epigenetic patterns can be observed in response to a wide range of environmental toxicants. Thus, we hold the opinion that there are clear benefits to using epigenetic marks as biomarkers of exposure, for reasons which will be discussed in this section. For instance, DNA methylation events are particularly attractive as biomarkers because of their relative robustness in different storage conditions ([@c108]; [@c290]; [@c324]).

Moreover, the properties of DNA methylation biomarkers as both stable and responsive to environmental cues make them attractive candidates as markers of exposure and predictive markers of disease ([@c168]). DNA methylation-based predictors of health and lifestyle factors such as smoking habits ([@c5]; [@c35]; [@c214]; [@c241], [@c242]), alcohol consumption ([@c214]), and body mass index ([@c214]) have been described and have been proposed as molecular predictors of disease and morbidity or as an alternative to self-reported measurements. Because epigenetic marks can persist even after cessation of the exposure, using epigenetic marks as biomarkers of exposure could be particularly useful in situations where the exposures tested have short half-lives *in vivo* ([@c168]).

As biomarkers of disease, epigenetic disease signatures, or episignatures, have been described in cancers ([@c73]), neurological diseases ([@c25]; [@c77]; [@c128]), and heart diseases ([@c254]) and may be applied as molecular predictors of disease or indicators of disease progression. Epigenetics-based diagnostic tests are already commercially available; examples include the DNA methylation-based Epi proColon® 2.0 CE (Epigenomics AG) for colorectal cancer ([@c171]) and the miRNA-based RosettaGX Reveal™ (Rosetta Genomics) for thyroid malignancies ([@c187]).

Episignatures as biomarkers have, in theory, the potential of capturing information on current tissue states, predisposition to disease, and the cumulative effects of environmental stressors and exposures. However, although carcinogenicity testing is an important component of testing for regulatory approval, the role of toxico-epigenomics in the risk assessment process has yet to be established ([@c130]; [@c250]).

Challenges of Applying Epigenetics in Toxicology {#s2.2}
------------------------------------------------

A major impediment to the application of epigenomic analysis in toxicology is the fact that consensus normal epigenomes have yet to be fully defined for all tissue and cell types ([@c283]; [@c292]). Given the large epigenetic variability within and between tissue types, age groups, and populations, reference epigenomes are particularly critical ([@c206]; [@c207]) because comparing epigenetic patterns across heterogeneous sample groups without suitable adjustment will, in our experience, substantially reduce statistical power.

These challenges could be overcome in the near future with the introduction of correction methods for cell-composition effects ([@c41]; [@c134]; [@c215]; [@c347]) and the generation of cell-type-specific epigenomic maps by large-scale initiatives of the International Human Epigenome Consortium ([@c50]), namely, Encyclopedia of DNA Elements (ENCODE) ([@c84]; [@c91]), the National Institutes of Health Roadmap Epigenomics Program ([@c252]), the BLUEPRINT projects ([@c102]), and the 4D Nucleome Project ([@c79]). The Toxicant Exposures and Responses by Genomic and Epigenomic Regulators of Transcription (TaRGET) program provides an invaluable resource of high-quality transcriptomic, epigenomic, and chromatin accessibility data from experimental *in vivo* systems that not only enables an improved understanding of the potential impacts of environmental exposures on the epigenome but also provides a means to better assess the utility of surrogate tissues ([@c317]). However, although these resources have brought unprecedented progress to the field, gaps remain in the representation of different human populations and phenotypes that need to be addressed.

Another challenge that especially affects the testing of EDCs is the fact that the health outcomes associated with exposure and epigenetic alterations can occur years or generations after the initial exposure. As discussed in previous sections, epigenetic impacts are often amplified when exposure occurs in early life ([@c18])---a vulnerable period that is not generally amenable to human testing. A further complication is the fact that epigenetic mechanisms act in concert to have a net functional effect on chromatin accessibility and gene regulation ([@c155]). Therefore, a single end point measure is often insufficient to gain a thorough understanding of the epigenotoxicity of a compound.

A potential solution for studying environmental chemicals (such as EDCs) with unknown or persistent effects is to conduct real-time observations of epigenetic states. In recent years, applications of reporter systems have enabled real-time observation of DNA methylation, enhancing our understanding of the dynamics of epigenetic states in development. For instance, *in vitro* reporters ([@c30]; [@c278]), fluorescent probes specific for DNA methylation ([@c166]), the MethylRO mouse ([@c297]), and the mCherry-MBD transgenic zebrafish line ([@c339]) enable users to observe spatial and temporal changes to epigenetic states. An application of fluorescence lifetime imaging-based Förster resonance energy transfer (FLIM-FRET) has demonstrated the interactions between epigenetic marks and the $\text{ER}\alpha$ and the disruption of these interactions by the antiestrogen tamoxifen ([@c189]). High-throughput applications of this approach could enable the screening of other endocrine regulators in response to a wide array of environmental chemicals. Other live-cell methods include bimolecular anchor detector (BiAD) sensors, which have been applied for the detection of DNA methylation and H3K9me3 levels in living cells ([@c196]). This system gives a fluorescence readout dependent on co-occurrent binding of epigenetic mark-specific detector proteins and site-specific anchor proteins, which are targeted to sites of interest by zinc-finger, transcription activator-like (TAL)-effector or clustered regularly interspaced short palindromic repeats (CRISPR)-dCas9 systems ([@c196]).

The third challenge is the limitations of current epigenomic assays. Current assays can be broadly divided into three categories: measurements of global epigenetic effects, locus-specific assays, and epigenome-wide methods. Commonly used measurements of global epigenetic effects include techniques such as high-performance liquid chromatography ([@c253]), mass spectrometry ([@c61]; [@c227]; [@c336]), dot blots ([@c147]), enzyme-linked immunosorbent assay (reviewed by [@c6]), luminometric methylation assays ([@c154]), and bisulfite pyrosequencing of repetitive elements ([@c330]). Cell-based reporter assays for global methylation have also been described ([@c14]; [@c335]). Although these techniques have undoubtedly produced valuable findings, potentially epigenotoxic compounds may induce locus-specific effects that are too subtle to be detected by these methods. Moreover, whereas DNA methylation levels in repetitive elements are often used as surrogates for global DNA methylation, these readings do not always correlate well with true global DNA methylation ([@c34]).

Techniques that enable locus-specific assays include bisulfite pyrosequencing, amplicon bisulfite sequencing, and cell-based reporter assays ([@c123]; [@c278]). *In vivo* models include intracisternal A-particle (IAP) mouse models, based on IAP retrotransposon reporter-type systems ([@c33]). IAP mouse models display a range of coat color and tail morphology changes that reflect epigenetic states in response to test materials administered to the mice. One limitation of these models is that changes in tail kinks and coat color may be subtle and could be subject to observer bias. Moreover, a limitation that affects all locus-specific assays is that *a priori* knowledge of the gene to be analyzed is required, making such assays less useful in screening for new epigenetic modifiers with unknown targets.

Epigenome-wide methods, as the name suggests, provides high resolution and coverage for the epigenetic mark analyzed. Requiring no *a priori* knowledge of potential targets, epigenome-wide methods enable the discovery of new biomarkers and target regions. Examples include DNA methylation arrays, reduced-representation bisulfite sequencing (RRBS) ([@c219]), histone chromatin immunoprecipitation sequencing (ChIP-seq) ([@c262]), and whole-genome bisulfite sequencing ([@c298]). These methods, although highly informative, are to our knowledge not currently amenable to miniaturization or cost effective for screening large libraries of compounds at a time. Nevertheless, this could change in the near future as more resources are dedicated to this field of study and the costs of sequencing and analysis are reduced.

Evidently, none of the discussed methods would be universally applicable. In a review by Rasoulpour et al. ([@c249]), the authors suggested that the ideal toxicology screen should be scalable to medium or high throughput, be *in vitro* based, be cost effective, have robust end points, and have good false-positive/negative rates ([@c249]). Although none of the methods discussed match such an ideal screening method ([Figure 2](#f2){ref-type="fig"}), future technological advances could make this a reality.

![Comparison of major techniques for epigenetics analyses on subjective scales for scalability and direct biological relevance. Axes are in arbitrary scales, with scalability denoting how amenable a given technique is to be implemented in a high-throughput screening setting. Direct biological relevance denotes how information-rich the results of a given technique are. Note: ATAC-seq, assay for transposase-accessible chromatin using sequencing; ChIP, chromatin immunoprecipitation sequencing; ELISA, enzyme-linked immunosorbent assay; HPLC, high-performance liquid chromatography; RRBS, reduced-representation bisulfite sequencing; WGBS, whole-genome bisulfite sequencing.](ehp-128-015001-g002){#f2}

One particularly exciting avenue of development is the rapid advance of genome editing technology. The relative efficiency and adaptability of CRISPR/Cas9/Cas12a ([@c54]; [@c82]) techniques could soon give rise to multi-end point, high-throughput, *in vitro* reporter assays for epigenetic modifiers. In our view, the first challenge to reach this goal is to identify robust and biologically relevant end points for which reporter assays could be generated. Future assays could reflect higher-order chromatin structures in biologically important regions of the chromatin, as opposed to being locus-specific. One of the most exciting new developments in the field has been the development and refinement of techniques that profile chromatin accessibility, whether by sequencing ([@c49]; [@c69]) or super-resolution imaging ([@c29]). As discussed previously, examining a single aspect of epigenetic regulation may often be insufficient, because epigenetic mechanisms typically work in concert. By assessing higher-order chromatin states, these techniques take into account the summation of these mechanisms. Although these methods are currently not as easily implemented in a high-throughput setting, further research in this field is certainly warranted.

Finally, it may also be argued that *in vitro* screening measures would be limited in identifying biologically relevant epigenetic toxicants. However, we hold the opinion that the implementation of screening programs is still useful because they could lead to the identification of highly epigenotoxic compounds, thus halting their use or introduction into the environment until further analyses are carried out. Moreover, it is worth noting that each class of method---whether *in vitro*, *in vivo*, *in silico*, or based on populations---will have a different capacity to provide different levels of evidence, as well as different strengths and weaknesses ([Figure 3A](#f3){ref-type="fig"}).

![An integrative method for investigating the impact of environmental chemicals on the epigenome and a proposed approach for toxico-epigenomic screening. (A) Comparison of *in silico*, *in vitro*, *in vivo*, population-based, and integrative methods in fully understanding the potential effects of environmental chemicals on the epigenome. Dotted arrows indicate situations where evidence can be inferred but not directly proved by the described methods. (B) An illustration of a proposed approach for toxicoepigenomic screening. A high-throughput screen (HTS) using *in vitro* and *in silico* methods can be conducted using single compounds and mixtures. Hits identified from the Tier 1 screen can be characterized more extensively using relevant *in vitro* and *in vivo* experiments. Finally, a systems toxicology approach could be used to integrate all data, including human data, to generate a complete profile of epigenotoxicology.](ehp-128-015001-g003){#f3}

Even assuming that all the technical challenges can be overcome, interpreting epigenetic results from the perspective of classical toxicology could still be complicated. For instance, if a change in epigenetic state is identified, is it truly an adverse event, or is it an early adaptive response? Is there a no-effect threshold when it comes to epigenetic modification?

Strategies for Toxico-Epigenomic Screening {#s2.3}
------------------------------------------

In addition to technical improvements, screening can be improved by reassessing current strategies for evaluating environmental toxicants as epigenetic modifiers. In this section, we discuss potential strategies for conducting epigenomic screening in the face of current technical limitations.

### Applying drug discovery pipelines for identifying epigenetic modifiers. {#s2.3.1}

Perspectives from the drug discovery pipeline could prove useful for developing similar approaches for toxicological screening. The burgeoning fields of computer-aided drug design and molecular docking have been successfully implemented for drug discovery processes ([@c197]). By using homology models of the DNMTs or, in theory, any of the epigenetic enzymes, it is possible to perform virtual screens of thousands of compounds at relatively little cost. As reviewed by Lu et al. ([@c195]), this approach has already led to the discovery of the DNMT inhibitors RG108, NSC14778, nanaomycin A, SET7 inhibitor DC_S100, and EZH2 inhibitor DCE_254, among others ([@c195]). This approach could also be applied in toxicology to screen for potential epigenetic disruptors. However, although *in silico* approaches offer invaluable opportunities for streamlining target discovery processes, this does not preclude the usual standards of *in vivo* and *in vitro* testing. It does, however, enable the prioritization of potential targets.

On a related point, another approach for identifying lead chemicals is to pinpoint molecular features that enable the identification of epigenetic perturbagens. To date, common features have been identified in a subset of epigenetic modifiers, for instance phenoxyacetic acid moieties in fibrates, and the presence of halogenated polycyclic features in DDT, polychlorinated biphenyls, and chlordane ([@c159]). This approach has been challenging because nongenotoxic epigenetic agents typically lack easily identifiable DNA-reactive chemical features. Moreover, as far as we know, the features identified in fibrates and polychlorinated compounds are not direct evidence of epigenetic-modifying ability. However, we expect that improvements in computational technology, artificial intelligence, and our understanding of the chemical processes underlying epigenetic modifications could bring new advances in this area of study.

Advances in high-content screening or high-content analysis (HCS/HCA) can also be adapted for toxico-epigenomics. HCS/HCA has been applied in drug discovery and has been driven by advances in automated microscopy and image analysis ([@c92]). An example of this is the recently described microscopic imaging of the epigenetic landscape (MIEL) system ([@c97]). In this approach, the authors applied HCS approaches for multiparametric staining and imaging of multiple epigenetic marks. They demonstrated that the MIEL machine-learning algorithm could accurately rank and classify epigenetically active drugs, proving that the imaging of epigenetic marks and chromatin states can be added to the battery of possible HCA phenotypic screens ([@c97]).

### Emulating the endocrine disruptor screening program. {#s2.3.2}

One overarching approach may be to emulate and extend the Endocrine Disruptor Screening Program (EDSP), which was implemented by the U.S. Environmental Protection Agency (EPA) in response to mounting concerns over EDCs ([@c101]). The EDSP screens for chemicals that could perturb estrogen, androgen, and thyroid systems in humans, fish, and wildlife and uses a pathway-based approach in which potential lead compounds are identified based on their interactions with endocrine pathways without relying on the observation of an adverse response or phenotypic end point ([@c174]).

The EDSP uses a two-tier framework. Tier 1 was designed as a screening tier, comprising multiple *in vitro* and *in vivo* test systems, which screen for a compound's potential to interact with endocrine pathways without considering potential adverse effects. Tier 2 was designed to test established adverse effects and the dose--response relationships of hits identified in Tier 1 of the program ([@c101]). Using a similar approach, epigenetic modifiers may first be identified based on their impact on epigenetic enzyme activity or chromatin states, using techniques that are readily implemented in a high-throughput setting. The idea is that given the importance of epigenetic machinery in determining cell fate and function, evidence that a compound is capable of influencing epigenetic enzyme activity sufficiently warrants additional research and testing. This approach is particularly useful when applied to epigenetic modifiers because of the breadth of possible health outcomes they could inflict.

Some limitations to this approach are that it is uncertain whether it allows for adequately sensitive detection ([@c68]). Moreover, without prior knowledge of apical or adverse outcomes, it is uncertain whether Tier 2 testing would adequately capture the toxicity profile of the test compounds and whether it accounts for differences in species and life stages ([@c68]). Some measures can be taken to at least in part mitigate the issue of sensitivity. For example, the U.S. EPA suggested in a report that assay sensitivity could be maximized while permitting an acceptable level of false positives, based on the assumption that false positives could be detected and eliminated in the second tier of the screen ([@c296]). Other approaches are to use multiple assays for each end point, from which weighted data can be determined ([@c257]); to use a screening strategy based on concentration--response curves as opposed to single-dose assays ([@c140]); and to use a compound set enrichment approach, whereby potential active chemicals are identified in sets rather than as individual compounds ([@c306]).

Adverse Outcome Pathways and Systems Toxicology---Filling in the Gaps {#s2.4}
---------------------------------------------------------------------

A potential solution to the limitations discussed above is to implement the adverse outcome pathway (AOP) paradigm ([@c10]). An AOP is a collection of data that connects an exposure to an adverse effect through a series of separate but overlapping pieces of evidence. In an AOP, a molecular initiating event (exposure to a toxicant) must be shown to induce a series of key events (e.g., DNA methylation change, transcriptional changes, sequence changes, cell proliferation), which in turn are shown to result in an adverse outcome (e.g., cancer, a disease state).

Although an AOP is itself a collection of correlative evidence, it provides a framework for organizing data across multiple disciplines in a biologically plausible and evidence-based manner. The AOP approach enables the integration of findings from epidemiology studies, which are generally observational associations between an exposure and adverse health outcomes, and *in vitro* and *in vivo* studies. The totality of this evidence can be used to establish a causative link between the exposure and the adverse outcome.

An application of AOPs is the systems toxicology strategy, which is based on the idea that any functional perturbation is a result of changes in genomic, proteomic, and metabolic states ([@c284]). Systems toxicology integrates classical toxicology with multiple levels of molecular data, with the aim of establishing causality via a chain of molecular events. Systems toxicology aims to describe adverse biological effects as perturbed networks, as opposed to empirical end points ([@c125]). This strategy has been made possible with advances in computational biology and molecular biology techniques.

However, the successful implementation and practice of systems toxicology requires characterization of exposures with regard to composition, dose, and duration, as well as extensive phenotypic and molecular profiling of standard biological model systems. Many of the building blocks for the widespread implementation of systems toxicology are already in place. For instance, the L1000 and Connectivity Map resources developed through the Library of Integrated Network-Based Cellular Signatures (LINCS) project enable the prediction of mechanisms of action based on the gene expression profile induced by a particular exposure ([@c180]). The connectivity framework has also been applied to define and compare proteomic and histone mark signatures ([@c188]). Other valuable resources include the Toxin and Toxin-Target Database (T3DB), which makes gene expression data on more than 3,600 compounds publicly available ([@c322]), and the ENCODE project, which provides systematic maps of regions of transcription, transcription factor association, chromatin structure, and histone modification ([@c91]).

Chemical Mixtures---Something from Nothing? {#s2.5}
-------------------------------------------

An additional consideration is the fact that real-life exposures typically occur as mixtures, as opposed to single agents ([@c156]). There have thus been concerns that the risks of complex chemical mixtures are not adequately assessed ([@c95]; [@c161]). A systematic review aimed at quantifying synergetic toxicity in mixtures identified evidence of synergistic interactions in a small subset of pesticides, metals, and antifoulant mixtures ([@c58]). Cedergreen ([@c58]) defined synergetic mixtures as those which elicited an observed effect that was at least 2-fold greater than the predicted effect, using concentration addition as a reference model.

As reviewed extensively by Bopp et al. ([@c37]), the challenge in realistically assessing exposure to mixtures is taking into account the target population(s), the timing of exposure, or whether individuals or organisms are exposed to mixtures simultaneously or sequentially ([@c37]). Kienzler et al. ([@c156]) described current and potential future tools for modeling mixture effects but indicated that further guidance, data, and expertise are required before they can be fully applied ([@c156]). However, the authors did note that there is still merit to assessing single substances because a thorough characterization of single agents could minimize uncertainties and the requirement for assumptions in the risk assessment of chemical mixtures ([@c156]).

An interesting proposal by Bornehag et al. ([@c38]) suggests that exposure mixtures should first be identified and reconstructed based on evidence from epidemiological and biomonitoring data ([@c38]). These mixtures can then be tested with *in vivo* experiments to determine a point of departure associated with the studied adverse health outcome, and the final step is to compare the similarity of the experimental data with outcomes measured in the human population ([@c38]). In addition to taking into account mixtures in the risk assessment process, this approach could enable the systematic integration of epidemiological and experimental evidence ([@c38]). We note that with this proposed notion, the mechanistic effects of combinations of chemicals---whether independent, additive, or synergistic---are not a primary concern; the main concern is that these mixtures are relevant based on epidemiological and biomonitoring data.

We also note that there could be merit to the screening of mixtures at the preliminary *in vitro* screening stage. This could, at least in part, enable the detection of synergetic xenobiotic combinations that might have been missed if the constituent chemicals were analyzed individually.

Bringing It All Together {#s2.6}
------------------------

Applying a combination of these approaches could prove useful in screening for epigenetic modifiers. For instance, we envision that assays for global changes in epigenetic or chromatin sates could be used in a manner analogous to the EDSP Tier 1 screening method. This screen may include mixtures of chemicals that have been identified and reconstructed through epidemiological observations or biomonitoring data, as described by Bornehag et al. ([@c38]). Hits identified in Tier 1 screens can be further examined with more sensitive epigenome-wide techniques, followed by the identification of phenotypic and molecular perturbations incurred by the exposure. Tier 2 screens may also include time-dependent, early life experiments in order to establish the full epigenotoxicity profile of the exposures in question. Pathway-enrichment technologies may then be applied to predict for epigenotoxicity, followed by AOP to organize preliminary data into coherent chains of evidence, and to identify areas in which further research is warranted. Finally, hit compounds may be characterized using systems toxicology approaches, ultimately resulting in comprehensive portraits of exposures and disease states ([Figure 3B](#f3){ref-type="fig"}).

Perspectives for the Future of the Field {#s2.7}
----------------------------------------

As with many aspects of molecular science, the field of epigenetics has benefited greatly from computational and analytical advances ([@c57]; [@c186]; [@c221]). Our view is that the future iterations of toxicology are unlikely to consider genetic, epigenetic, or proteomic factors individually, with more calls to consider the totality of these mechanisms using multi-omics analyses. This new horizon of possibilities allows for more optimistic and ambitious concepts for the future of toxicology.

Another interesting concept is to generate fingerprints of exposure to environmental toxicants using evolving -omics technologies ([@c223]) and apply these signatures as biomarkers and predictors of response. An important step toward this is to establish robust and universally recognized epimutation signatures, analogous to the mutational signatures established by genome sequencing ([@c163]). Our view is that a compendium of epigenomic signatures will enable systematic comparisons between test compounds. An educated guess of an unknown compound's mechanism of action could be made, for example, based on the epimutation signature it induces in reference to known entries. With additional information on toxicity and adverse outcomes, it may be possible to make calls on how hazardous a compound is based on its epigenomic and mutational signature. Libraries of phosphoproteomics and chromatin profiles are already in development, using the connectivity framework developed with the LINCS Connectivity Map in the context of epigenetics ([@c71]; [@c188]). The availability and growth of these resources represent exciting opportunities for the future of epigenomic research.

In an extension of -omics analyses, one of the most ambitious concepts is that of the exposome, which is defined as a summation of an individual's experiences over the course of his or her lifetime, and the biological response to these exposures ([@c320]). The exposome is represented by molecular measurements influenced by a lifetime of exposure to a variety of factors such as diet, lifestyle, infections, and psychosocial factors ([@c320]). The Human Exposome Project, the environmental analog of the Human Genome Project, is a mammoth undertaking, because the possible range of exposures and individual response is immensely complex ([@c229]). Exposome research projects include the Human Early Life Exposome (HELIX) ([@c314]), enhanced exposure assessment and omic profiling for high priority environmental exposures in Europe (EXPOsOMICS) ([@c311]), Health and Exposome Research Center: Understanding Lifetime Exposures (HERCULES) ([@c229]), and Health and Environment-wide Associations based on Large population Surveys (HEALS) (<http://www.heals-eu.eu/>; [@c259]) projects. Although many of the proposed ideas are not feasible at present, the concept of the exposome has important implications for the assessment of exposure in human health research; for instance, considerations that environmental exposures do not exist in isolation and that individual response to exposures can be influenced by a multitude of inherent or acquired factors.

In our view, another major issue to consider in the future is how well current assays are adapted for measuring the environmental impact of chemical agents resulting from human activity. Currently, most high-throughput assays are based on end point measures relevant to humans or mammals. Although this is of clear importance, a holistic assessment of the impact of chemical agents on the environment would require the development of robust nonmammalian or cross-species assays ([@c68]).

Conclusion {#s3}
==========

Significant advancements in analytical technologies are now enabling more robust testing and risk assessment approaches in evaluating the hazards of environmental chemical exposure. With accumulating evidence that environmental chemicals are at least partially responsible for the onset of various noncommunicable diseases, there is an urgent need to understand the mechanisms underlying chemical-induced adverse outcomes. Considering epigenetic modifications in the risk assessment process could lead to the development of more sensitive and predictive assays for detecting chemical-induced changes. In view of the impact that environmental chemicals could have on the environment, and on current and future generations, increased efforts in research and regulation are certainly warranted.
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